{"drugs":["Dronabinol","Marinol"],"mono":{"0":{"id":"192630-s-0","title":"Generic Names","mono":"Dronabinol"},"1":{"id":"192630-s-1","title":"Dosing and Indications","sub":[{"id":"192630-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>AIDS - Loss of appetite:<\/b> initial, 2.5 mg ORALLY twice daily, before lunch and dinner; may reduce to 2.5 mg\/day, given ORALLY in the evening or at bedtime if usual dose is intolerable; adjust to optimal clinical response, MAX 20 mg\/day<\/li><li><b>Chemotherapy-induced nausea and vomiting; Prophylaxis:<\/b> 5 mg\/m(2) ORALLY 1 to 3 hr before chemotherapy, 5 mg\/m(2) ORALLY every 2 to 4 hr after chemotherapy for a total of 4 to 6 doses\/day; may increase dose by 2.5 mg\/m(2) increments to MAX dose of 15 mg\/m(2)\/dose<\/li><\/ul>"},{"id":"192630-s-1-5","title":"Pediatric Dosing","mono":"<b>Chemotherapy-induced nausea and vomiting; Prophylaxis:<\/b> 5 mg\/m(2) ORALLY 1 to 3 hr before chemotherapy, 5 mg\/m(2) ORALLY every 2 to 4 hr after chemotherapy for a total of 4 to 6 doses\/day; may increase dose by 2.5 mg\/m(2) increments to MAX dose of 15 mg\/m(2)\/dose "},{"id":"192630-s-1-6","title":"Dose Adjustments","mono":"<b>elderly:<\/b> start at the low end of the dosing range "},{"id":"192630-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>AIDS - Loss of appetite<\/li><li>Chemotherapy-induced nausea and vomiting; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Postoperative nausea and vomiting; Treatment and Prophylaxis<br\/>"}]},"3":{"id":"192630-s-3","title":"Contraindications\/Warnings","sub":[{"id":"192630-s-3-9","title":"Contraindications","mono":"hypersensitivity to dronabinol, cannabinoid, sesame oil, or any other components of this product <br\/>"},{"id":"192630-s-3-10","title":"Precautions","mono":"<ul><li>alcohol abuse or dependence; risk of dronabinol abuse\/physical dependence<\/li><li>cardiac disorders; hypotension, hypertension, syncope, or tachycardia may occur<\/li><li>elderly; may be more sensitive to adverse effects<\/li><li>hazardous activities, such as operating machinery or driving; may impair cognitive and motor performance<\/li><li>psychiatric illness (mania, depression, or schizophrenia); may exacerbate<\/li><li>seizure disorder, history; may lower the seizure threshold<\/li><li>substance abuse, history; risk of dronabinol abuse\/physical dependence<\/li><\/ul>"},{"id":"192630-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"192630-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"192630-s-4","title":"Drug Interactions","sub":{"1":{"id":"192630-s-4-14","title":"Major","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Topotecan (theoretical)<\/li><\/ul>"}}},"5":{"id":"192630-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Hypotension, Palpitations, Tachyarrhythmia, Vasodilatation<\/li><li><b>Dermatologic:<\/b>Flushing<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (3% to 10%), Nausea (3% to 10%), Vomiting (3% to 10%), Xerostomia (38% and 50%)<\/li><li><b>Neurologic:<\/b>Amnesia, Ataxia, Confusion, Coordination problem, Dizziness (3% to 10%), Somnolence (3% to 10%), Vertigo<\/li><li><b>Psychiatric:<\/b>Anxiety, Delusion of persecution, Depersonalization, Depression, Disturbance in thinking (3% to 10%), Euphoria (3% to 10%), Hallucinations<\/li><\/ul>"},"6":{"id":"192630-s-6","title":"Drug Name Info","sub":{"0":{"id":"192630-s-6-17","title":"US Trade Names","mono":"Marinol<br\/>"},"2":{"id":"192630-s-6-19","title":"Class","mono":"<ul><li>Antiemetic<\/li><li>Cannabinoid<\/li><\/ul>"},"3":{"id":"192630-s-6-20","title":"Regulatory Status","mono":"Schedule III<br\/>"},"4":{"id":"192630-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"192630-s-7","title":"Mechanism Of Action","mono":"<ul><li>The exact mechanism of action of dronabinol is not known. Cannabinoid receptors in neural tissues may mediate the effects of dronabinol and other cannabinoids.   Animal studies with other cannabinoids suggest that dronabinol's antiemetic effects may be due to inhibition of the vomiting control mechanism in the medulla oblongata. <\/li><li>Central sympathomimetic activity    may result in tachycardia and\/or conjunctival injection.   Dose-related reversible effects on appetite, mood, cognition, memory, and perception also occur, subject to great interpatient variability. <\/li><\/ul>"},"8":{"id":"192630-s-8","title":"Pharmacokinetics","sub":[{"id":"192630-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration: 2 to 4h<\/li><li>Bioavailability: 10 to 20%<\/li><\/ul>"},{"id":"192630-s-8-24","title":"Distribution","mono":"Vd: 10 L\/kg <br\/>"},{"id":"192630-s-8-25","title":"Metabolism","mono":"<ul><li> Hepatic: extensive first-pass<\/li><li>Metabolite: 11-OH-delta-9-THC (active)<\/li><\/ul>"},{"id":"192630-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 35% to 50%<\/li><li>Renal: 10 to 15%<\/li><\/ul>"},{"id":"192630-s-8-27","title":"Elimination Half Life","mono":"19 to 36 h.<br\/>"}]},"9":{"id":"192630-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>store in the refrigerator or in a cool environment between 8 to 15 degrees Celsius (46 to 59 degrees Fahrenheit); do not freeze <br\/>"},"10":{"id":"192630-s-10","title":"Monitoring","mono":"<ul><li>psychiatric symptoms in patients with mania, depression, or schizophrenia<\/li><li>HR<\/li><\/ul>"},"11":{"id":"192630-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Capsule, Liquid Filled: 2.5 MG, 5 MG, 10 MG<br\/><\/li><li><b>Marinol<\/b><br\/><ul><li>Oral Capsule: 2.5 MG<\/li><li>Oral Capsule, Liquid Filled: 5 MG, 10 MG<\/li><\/ul><\/li><\/ul>"},"13":{"id":"192630-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position to lessen dizziness.<\/li><li>This drug may cause flushing, nausea, vomiting, xerostomia, ataxia, confusion, coordination problem, dizziness, somnolence, vertigo, disturbance in thinking, or euphoria. Elderly patients may be more sensitive to adverse effects.<\/li><li>Drug may lower the seizure threshold in patients with a history of seizure disorder.<\/li><li>Patient should report persistent signs\/symptoms of hypotension, palpitations, or tachyarrhythmia.<\/li><li>Drug may exacerbate psychiatric illness. Patient should report increase in signs\/symptoms of mania, depression, or schizophrenia.<\/li><li>Patient should avoid drinking alcohol during drug therapy.<\/li><\/ul>"}}}